Affordable Access

Access to the full text

The Role of HMGB1 in Traumatic Brain Injury—Bridging the Gap Between the Laboratory and Clinical Studies

Authors
  • Manivannan, S1
  • Wales, E2
  • Zaben, M3, 2
  • 1 Southampton General Hospital, Southampton, UK , Southampton (United Kingdom)
  • 2 Cardiff University, Cardiff, UK , Cardiff (United Kingdom)
  • 3 University Hospital of Wales, Heath Park Way, Cardiff, CF14 4XW, UK , Cardiff (United Kingdom)
Type
Published Article
Journal
Current Neurology and Neuroscience Reports
Publisher
Springer-Verlag
Publication Date
Dec 06, 2021
Volume
21
Issue
12
Identifiers
DOI: 10.1007/s11910-021-01158-3
Source
Springer Nature
Keywords
Disciplines
  • Topical Collection on Neurotrauma
License
Yellow

Abstract

Purpose of ReviewTraumatic brain injury (TBI) is amongst the leading causes of mortality and morbidity worldwide. However, several pharmacological strategies in the clinical setting remain unsuccessful. Mounting evidence implicates High Mobility Group Box protein 1 (HMGB1) as a unique alternative target following brain injury. Herein, we discuss current understanding of HMGB1 in TBI and obstacles to clinical translation.Recent FindingsHMGB1 plays a pivotal role as a ‘master-switch’ of neuro-inflammation following injury and in the regulation of neurogenesis during normal development. Animal models point towards the involvement of HMGB1 signalling in prolonged activation of glial cells and widespread neuronal death. Early experimental studies demonstrate positive effects of HMGB1 antagonism on both immunohistochemical and neuro-behavioural parameters following injury. Raised serum/CSF HMGB1 in humans is associated with poor outcomes post-TBI.SummaryHMGB1 is a promising therapeutic target post-TBI. However, further studies elucidating receptor, cell, isoform, and temporal effects are required prior to clinical translation.

Report this publication

Statistics

Seen <100 times